Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Stock Short Interest Rises 1,343.5%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 229,146 shares, an increase of 1,343.5% from the September 30th total of 15,874 shares. Based on an average daily volume of 954,798 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the company’s stock are short sold.

Oncotelic Therapeutics Trading Down 3.7%

Oncotelic Therapeutics stock traded down $0.00 during mid-day trading on Wednesday, hitting $0.02. 170,000 shares of the company’s stock were exchanged, compared to its average volume of 297,771. Oncotelic Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.11. The stock has a 50 day moving average of $0.03 and a two-hundred day moving average of $0.04. The stock has a market cap of $8.31 million, a P/E ratio of 0.03 and a beta of -0.18.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc is a biotechnology company focused on developing therapeutics for cancer and other serious diseases. Its research platform centers on RNA-based medicines, including antisense oligonucleotides designed to regulate disease-related genetic signals and immune responses.

The company’s leading investigational product is OT-101, also known as trabedersen, an antisense oligonucleotide intended to inhibit transforming growth factor beta 2 (TGF-β2). Oncotelic has evaluated OT-101 in oncology indications including glioblastoma, pancreatic cancer and melanoma, although the product remains investigational and is not approved as a commercial treatment.

Oncotelic was formerly known as Mateon Therapeutics and adopted its current name as it refined its focus on oncology and related therapeutic programs.